CESTAT Chennai Upholds Scientific Classification of Levocarnitine Imports

Date: 20.09.2025

In a landmark decision, the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Chennai, has ruled in favor of M/s. ​ Symbio Generics India Private Ltd., upholding the classification of their imported products, “Levocarnitine” and “Levocarnitine L-Tartrate,” under Customs Tariff Heading (CTH) 29239000 as “Quaternary Ammonium Salts.” ​ This decision, pronounced on September 19, 2025, sets a significant precedent in the realm of customs classification disputes.

The dispute arose when the Revenue challenged the classification declared by the importer, M/s. ​ Symbio Generics India Private Ltd., and sought to reclassify the products under CTH 21069099 as “food preparations not elsewhere specified or included.” ​ The Revenue’s contention was based on the assumption that the imported goods were food supplements, despite expert opinions and scientific evidence supporting the original classification. ​

The products in question, “Levocarnitine” and “Levocarnitine L-Tartrate,” are pharmaceutical-grade compounds used as drug intermediates. ​ They are scientifically defined as “Quaternary Ammonium Salts” and have therapeutic value. ​ The Appellant argued that these products are separate chemically defined organic compounds, as per Note 1(a) of Chapter 29 of the Customs Tariff Act, 1975.

Handy Download:


Discover more from π€πšππ«π’π€πšπš π‹πžπ πšπ₯ π’πžπ«π―π’πœπžπ¬ (𝐀𝐋𝐒)

Subscribe to get the latest posts sent to your email.

Comments

One response to “CESTAT Chennai Upholds Scientific Classification of Levocarnitine Imports”

  1. […] CESTAT Chennai Upholds Scientific Classification of Levocarnitine Imports […]

Leave a Reply

Discover more from π€πšππ«π’π€πšπš π‹πžπ πšπ₯ π’πžπ«π―π’πœπžπ¬ (𝐀𝐋𝐒)

Subscribe now to keep reading and get access to the full archive.

Continue reading

Discover more from π€πšππ«π’π€πšπš π‹πžπ πšπ₯ π’πžπ«π―π’πœπžπ¬ (𝐀𝐋𝐒)

Subscribe now to keep reading and get access to the full archive.

Continue reading